Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
The standard regimen for the treatment of newly diagnosed primary CNS lymphoma (PCNSL) remains regimens that contain high-dose methotrexate (MTX). While these regimens can provide control for some patients, there is a dearth of options for the treatment of patients with PCNSL who cannot tolerate MTX...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis Group
2020-03-01
|
| Edice: | CNS Oncology |
| Témata: | |
| On-line přístup: | https://www.futuremedicine.com/doi/10.2217/cns-2019-0022 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|